“The data suggests this is a more transmissible virus with significant degrees of immune escape, that is going to render the vaccines less effective,” said one expert.
that the result was “better than I expected for Omicron,” showing that the variant was still vulnerable to vaccines overall and that it infected cells in a manner similar to other variants. In showing that the variant only incompletely evaded vaccines, the study also suggested that shots should remain effective against severe disease, especially when supplemented with a booster.
That said, the results overall reported a 40-fold drop in antibody activity against the Omicron variant as compared to vaccine antibody neutralization of the original SARS-CoV-2 strain of coronavirus, a much larger evasion than was seen from other variants. The blood plasma study is still a preprint and has not yet gone through peer review by other scientists, raising some caution, but not enough to outweigh its newsworthiness, said experts.
“I think there's consensus among us that even though the numbers are small, that they're coming from a reputable lab that's done this before and are not surprising,” said infectious disease expert Bruce Walker of the Massachusetts Consortium on Pathogen Readiness.
Fauci also described “very preliminary” study results, also from South Africa, that the Omicron variant tended to produce less severe disease than past ones. “Hopefully in the next few weeks we’ll get a much clearer picture,” he said. “But it appears that with the cases that are seen, we are not seeing a very severe profile of disease.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Pfizer vaccine 'partially protective' against OmicronOmicron variant of the coronavirus can partially evade the protection from Pfizer and partner BioNTech's vaccine, new research shows
Weiterlesen »
Omicron significantly reduces Covid antibody protection in small study of Pfizer vaccine recipients
Weiterlesen »
Vir, GSK's COVID-19 antibody treatment works against omicron in a lab study, and WHO no longer recommends convalescent plasmaThe emergence of omicron in recent weeks has set off a chain reaction among COVID-19 drug and vaccine makers, which are now conducting laboratory studies evaluating how well their therapies and shots work against omicron.
Weiterlesen »
Glaxo Says Its Covid-19 Antibody Drug Works Against OmicronGlaxoSmithKline and Vir said their Covid-19 antibody treatment retained effectiveness against the Omicron variant in laboratory studies, even as early data suggests that similar treatments work less well against the strain.
Weiterlesen »
10 Russian citizens returning from South Africa positive for COVID, 2 with Omicron VariantRussia announced the first cases of Omicron variant after 10 citizens returned from South Africa and tested positive for COVID, two of which were for Omicron.
Weiterlesen »